We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis’ Afinitor Gets EU Approval to Treat Pancreatic Tumors
Novartis’ Afinitor Gets EU Approval to Treat Pancreatic Tumors
September 6, 2011
The European Commission is expanding the indication for Novartis’ Afinitor to include treatment of advanced pancreatic neuroendocrine tumors (PNET) following the FDA’s May approval for the indication.